WALTHAM, MA– Revvity, a Waltham-based life sciences and diagnostics company, reported a 4.3% increase in third-quarter revenue to $729 million, supported by growth in its life sciences business and improved operating margins, as the company raised its financial outlook for 2026.
Revenue increased from $699 million in the same quarter last year, while earnings per share from continuing operations rose to $0.56 from $0.41, representing an increase of approximately 36.6%.
The company reported operating income from continuing operations of $95 million for the quarter ended October 4, 2026, compared with $82 million a year earlier. Its operating profit margin improved to 13.1% from 11.7%.
Adjusted earnings per share increased 16.9% to $1.38 from $1.18 in the third quarter of 2025.
Adjusted operating income climbed to $209 million from $182 million, while the adjusted operating profit margin expanded to 28.7% from 26.1%.
“Our exceptional third quarter performance demonstrates the momentum building across Revvity, as broad-based growth and strong execution drove results meaningfully ahead of our expectations,” said Prahlad Singh, President and Chief Executive Officer of Revvity. “With end market conditions continuing to improve, a strong pipeline of innovation, and the benefits of our transformation increasingly evident in our results, Revvity is extremely well positioned to capitalize on the opportunities ahead.”
Revvity’s Life Sciences division generated $380 million in quarterly revenue, up 10.8% from $343 million in the corresponding period last year.
The division recorded adjusted operating income of $119 million, compared with $101 million a year earlier. Its adjusted operating profit margin improved to 31.5% from 29.5%.
On a pro forma basis, Life Sciences revenue increased 11%, while organic revenue grew 9%, reflecting growth in the company’s research technologies and related businesses.
The Diagnostics division reported revenue of $349 million, down approximately 2% from $356 million in the third quarter of 2025.
Despite the decline in reported revenue, the division’s adjusted operating income increased to $104 million from $89 million. Its adjusted operating profit margin expanded to 29.9% from 25.1%.
On a pro forma basis, Diagnostics revenue increased 4%, with organic growth of 5%.
Revvity also provided financial results excluding its Immunodiagnostics business in China, which the company is in the process of selling.
The planned divestiture involves a business that accounted for approximately 6% of Revvity’s total revenue in fiscal 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals and other customary conditions.
Excluding the China business, Revvity reported pro forma third-quarter revenue of $710 million, compared with $660 million a year earlier, an increase of approximately 7.4%.
Pro forma earnings per share from continuing operations rose to $0.60 from $0.40, while pro forma operating income increased to $102 million from $77 million.
The company’s pro forma operating profit margin improved to 14.3% from 11.7%.
On an adjusted pro forma basis, earnings per share increased to $1.37 from $1.13. Adjusted operating income rose to $209 million from $172 million, with the corresponding profit margin expanding to 29.4% from 26%.
Following its third-quarter performance, Revvity raised its financial guidance for the full year.
The company now expects approximately $2.86 billion in pro forma revenue for 2026, excluding the China Immunodiagnostics business.
It also forecasts pro forma organic revenue growth of approximately 5% and adjusted earnings per share between $5.40 and $5.45 for the full year.
Revvity’s updated outlook reflects management’s expectations for continued business growth and improving market conditions across its life sciences and diagnostics operations.
The company is scheduled to hold its 2026 Investor Day on November 13, when senior executives will discuss business priorities, operational developments, and the company’s financial outlook.
Revvity provides technologies, products, and services used in pharmaceutical research, biotechnology, laboratory diagnostics, and healthcare.
Its business includes technologies supporting biomarker identification, molecular research, imaging, disease screening, diagnostics, and scientific data analysis.
The company reported approximately $2.9 billion in revenue in 2025 and employs about 11,000 people worldwide. Revvity serves pharmaceutical companies, biotechnology firms, diagnostic laboratories, academic institutions, and government organizations in more than 160 countries.
Revvity is a member of the S&P 500 index.
